ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing, and commercialization of medical devices for wound management and surgical soft tissue repair.
ACell’s core product portfolio is based on our platform MatriStem UBM™ technology. The devices are extracellular matrices that facilitate the body’s ability to remodel site-appropriate, functional tissue.
ACell is committed to remaining an innovative leader in regenerative medical technology, leveraging our cutting-edge platform technology with the aim of solving complex clinical problems in healing.
Delivering Solutions in Regenerative Medicine
ACell has a team of more than 150 highly-trained account managers focused on providing health care professionals with product information, case support, and customer service.
Research & Development
ACell maintains robust product development and research programs dedicated to expanding the clinical indications for our products and helping more patients. Our product pipeline offers further opportunities to impact current and new markets.
Ethics & Compliance
ACell is committed to conducting its business ethically and to observing all applicable law, rules, and regulations. All employees and directors are regularly trained on corporate and compliance polices, and each member of the ACell team takes ACell’s commitment to business ethics seriously.